Confirmed Exhibitors

AbbVie Oncology

At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody, and CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

abbvie.com/oncology

Accord Healthcare

Headquartered in the United Kingdom, Accord Healthcare is a fast-growing global pharmaceutical company that develops, manufactures and distributes medicines in over 85 countries worldwide, helping to improve access for patients to vital pharmaceutical care. Our approach is agile and inventive, we’re driven to think differently by continuing to explore and deliver high quality medicines designed to benefit patients’ lives worldwide. 

accord-healthcare.com

AEACaP Asociación Española de Afectados de Cáncer de Pulmón

The Spanish Association of Lung Cancer Patients (Asociación Española de Afectados de Cáncer de Pulmón AEACaP) is a non-profit organization established in December 2008 to support individuals diagnosed with lung cancer. As Spain’s sole association dedicated exclusively to this disease, AEACaP offers free psychological support, legal advice, and guidance on medical consultations to patients and their families. The organization also promotes research to improve treatment options and quality of life, conducts informational activities to raise awareness, and advocates for equal access to healthcare services across all regions.

afectadoscancerdepulmon.com

ALCMI

ALCMI is a nonprofit international consortium comprised of 25 of the world’s premier oncology research institutions. We partner with the top minds from the most respected medical facilities, providing financial support and access to a team of experts and staff to assist in launching and managing investigator-initiated trials. We bridge the gap between clinical research organizations (CROs) and site management organizations (SMOs), resulting in a streamlined, agile process for quickly funding and initiating lung cancer research projects.

alcmi.org

American Association For Cancer Research (AACR)

The mission of the American Association for Cancer Research (AACR) is to prevent and cure cancer through: Research, Education, Communication, Collaboration, Science Policy and Advocacy, and Funding for Cancer Research. Through its programs and services, the AACR fosters research in cancer and related biomedical science, accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer, promotes science education and training, and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

aacr.org

Amgen

Amgen harnesses the best of biology and technology to make people’s lives easier, fuller and longer. We draw upon our deep knowledge of science to push beyond what’s known today. With roots in the biotech revolution, we are one of the world’s leading independent biotech companies.

amgen.com

AstraZeneca

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to deliver life-changing medicines to patients.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death. 

astrazeneca.co.uk

Bayer

Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise includes both marketed products and clinical development compounds, which reflect the company’s approach to research: prioritizing targets and pathways with the potential to impact the way that cancer is treated.

bayer.com

BioNTech

BioNTech is a global immunotherapy company pioneering novel therapies for cancer. Its diversified oncology portfolio consists of complementary therapeutic modalities, including mRNA immunotherapies, next-gen immunomodulators and targeted therapies.

biontech.com/int/en

Boehringer Ingelheim

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.

boehringer-ingelheim.com

Bristol Myers Squibb

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.

bms.com

British Thoracic Oncology Group (BTOG)

The British Thoracic Oncology Group (BTOG) is the multi-disciplinary group for healthcare professionals involved with thoracic malignancies throughout the UK.

BTOG’s mission is to support and educate thoracic oncology healthcare professionals, creating a professional community to exchange ideas, information, and innovation and to foster the development of research. The overall aim is to represent the needs of people with thoracic malignancies in the UK and ensure they have equitable access to optimal care. The vision is to contribute to achieving survival rates equal to the best in the world.

btog.org

Caris Life Sciences

Caris Life Sciences® is a leading next-generation AI TechBio company and precision medicine pioneer actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (DNA, RNA and proteins) and the application of AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease.

carislifesciences.com

Catalyst Pharmaceuticals, Inc.

Catalyst is committed to developing and commercializing novel medicines for patients living with rare and difficult to treat neurological diseases. 

catalystpharma.com

Daiichi Sankyo, Inc.

With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.

daiichisankyo.com

Eli Lilly and Company

Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. 

lilly.com

Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer and other serious diseases. Genmab’s proprietary pipeline includes bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

genmab.com

Gilead Oncology

Gilead Oncology is working to transform how cancer is treated. We are innovating with next generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody drug conjugates and small molecules to cell therapy based approaches, we are creating new possibilities for people with cancer.

global.askgileadmedical.com

Global Lung Cancer Coalition

The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.

lungcancercoalition.org

Gradiant Bioconvergence (GBCC)

Gradiant Bioconvergence (GBCC) is an organization developing patient-derived cancer organoids (PDOs) in a global scale. We have built Asia’s largest repository of PDOs with next-generation sequencing of over 700 models from patients with lung, gastric, colorectal, pancreas, and ovarian cancer. In addition, we are developing co-culture systems with autologous immune cells. Our PDO models are available for drug evaluation services. Based on our genomic and drug response data, we are discovering and validating novel oncology targets through our AI-driven target discovery and CRISPR-based PDO platform. Beyond cancer, GBCC has established brain organoids from hiPSCs for drug evaluation and disease modeling.

gradiantbio.com

ImmunityBio

ImmunityBio develops therapies and vaccines to defeat cancers and infectious diseases, going beyond checkpoint inhibitors to bolster the immune system to deliver durable, safe protection. ANKTIVA® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer, T- and memory T cells for long-duration response. Learn more at

anktiva.com

Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.”

innovativemedicine.jnj.com/emea

KRAS Kickers

The KRAS Kickers mission is to connect people to current research, resources, and community to kick cancer’s KRAS! KRAS kickers members engage with leading doctors, researchers, and advocates to learn about new developments and clinical trials, connect to resources, build community, and share their stories to give hope to all with a KRAS biomarker.

kraskickers.org

Median Technologies

Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD) for the early diagnosis of lung and liver cancers. Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies.

mediantechnologies.com

MSD

At MSD, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, MSD is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

msd.com

Nuvalent, Inc.

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

nuvalent.com

Nuvation Bio

Nuvation Bio is a late clinical-stage, global biopharmaceutical company focused on treating patients with the most difficult-to-treat cancers for which conventional therapies have failed.

nuvationbio.com

Oncoscope-AI

Oncoscope-AI is a comprehensive medical decision-support tool developed by a team of oncology scientists and AI experts. The software conducts daily Cochrane-level literature reviews supported by an agentic system of large language models, extracting 32 key variables from each relevant oncology publication into a structured database. 100% human reviewed and cross-checked, the results data are integrated with treatment paths from national guidelines and cross-linked with FDA and clinical trial registries. Designed for oncology professionals, the intuitive, interactive platform offers individual and institutional subscription options delivering real-time clinical data, empowering oncologists to make timely informed treatment decisions that improve patient outcomes.

oncoscope-ai.com

Pfizer Oncology

Pfizer Oncology is at the forefront of a new era in cancer care. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives

pfizer.com

PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

pharmamar.com

Predicine

Predicine is a global molecular insights company committed to advancing precision medicine in oncology. Predicine is developing proprietary technologies for cfDNA and cfRNA liquid biopsy to enable minimally invasive molecular diagnoses for early cancer detection, treatment selection, therapy response, minimal residual disease monitoring, and disease progression. Predicine’s portfolio includes blood, urine, tissue based NGS assays designed for globally harmonized use in clinical trial, companion diagnostic (CDx) development, and commercialization. Through its business operations in Silicon Valley, Houston, Chicago and Shanghai, Predicine is partnering and collaborating with leading biopharma companies, institutions, and governments to support personalized healthcare on a global scale.

predicine.com

Qure.ai

Qure.ai is a health-tech company that uses Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide.

Our solutions power the efficient detection, measurement and tracking of Lung Cancer to support clinicians and hospital administrators. We empower healthcare by helping to diagnose conditions early, prioritize treatment planning and ultimately improve the quality of patient life.

qure.ai

Regeneron

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, and through research initiatives such as the Regeneron Genetics Center.

regeneron.com

Revolution Medicines

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.

revmed.com

Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.

Roche is also the world leader in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. For more information, please visit roche.com.

roche.com

Scanlan International

Since 1921, the Scanlan family has been dedicated to hand-crafting the world’s finest surgical instruments. Explore our Scanlan® LEGACY Needle Holders and Forceps, showcasing the revolutionary Scan-II™ handle design. Our comprehensive range includes Scanlan® VATS instruments such as D’Amico Clamps, Suctions, Biopsy Forceps, Gonzalez-Rivas Dissector, Rocco Nodule Clamps, and Khan Decortication Grasper. Join us on our continued journey of excellence in surgical solutions.

scanlaninternational.com

Summit Therapeutics

Summit is a biopharmaceutical oncology company focused on resolving serious unmet medical needs. Summit’s compound, ivonescimab, is a novel, potential first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with anti-angiogenesis effects of anti-VEGF in a single molecule. Ivonescimab displays cooperative binding to these targets with increased avidity in the tumor microenvironment. Summit’s Phase III NSCLC trials include HARMONi (enrolled: NCT06396065), HARMONi-3 (enrolling: NCT05899608), HARMONi-7 (enrolling: NCT06767514). Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s NMPA.

smmttx.com

Takeda

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. Our therapies for hematologic cancers and solid tumors have helped transform the treatment landscape for previously underserved patients. Building on this leadership, we are advancing a pipeline focused on the power of innate immunity. Our goal is to introduce new classes of immunotherapies that can lead to deep, durable responses so more patients can benefit from innovative medicines.

takedaoncology.com

Thermo Fisher Scientific

Thermo Fisher Scientific is the world leader in serving science. We provide a comprehensive suite of solutions for precision oncology, spanning early development through commercial strategy, encompassing companion diagnostics. Our leading clinical research services enable customers to accelerate innovation and increase development productivity. Our advanced next-generation sequencing technology, Oncomine™ Solutions, enables laboratories everywhere to deliver genomic profiling from solid tumors and hematological cancers in as little as one day.

thermofisher.com/oncomine

1Cell.Ai

1Cell.Ai, based in Foster City, California, is at the forefront of precision oncology, driving personalized cancer therapy with its innovative single cell multi-omics platform combining cutting-edge molecular science with advanced AI technology. This platform delivers real-time information allowing for the comprehensive analysis of individual cancer cells across multiple molecular levels, including genomics, transcriptomics, proteomics, and epigenomics. This technology provides deep insights into tumor heterogeneity, enabling the identification of rare cell populations that may drive metastasis or resistance to therapy, and tailoring treatments to improve patient outcomes.

1cell.ai

Annalise.ai

Annalise.ai, Harrison.ai’s radiology AI solution, empowers clinicians to deliver more accurate and efficient radiology results throughout the imaging workflow. The comprehensive AI solutions detect up to 124 findings on chest X-rays and up to 130 findings on non-contrast head CT scans and can be customised for a wide range of care settings.

The solutions are clinically available in 40+ countries and deployed at 1,000+ sites in Australia, APAC, US, UK, EU and the Middle-East. Their CT Chest solution will be launching in Europe in 2026.

annalise.ai

Miconvey

Miconvey Technologies Co., Ltd., guided by the mission of “All Efforts For Health”, is a national high-tech enterprise specializing in minimally invasive surgical instruments. As a subsidiary of Hemony Pharmaceuticals Group, Miconvey has established a comprehensive system encompassing research & development, manufacturing, and sales. Its core products include ultrasonic scalpel systems, manual and powered staplers, and endoscopy. Miconvey’s products have obtained multiple international certifications, including China NMPA, EU CE, U.S. FDA, and Korea KFDA, with a business footprint in over 50 countries and regions worldwide.

miconvey.com

Natera

Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment response monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. Signatera is personalized and tumor-informed, providing each individual with a customized blood test, tailored to fit the unique signature of clonal mutations found in that individual’s tumor. Signatera is intended to detect and quantify cancer left in the body, at levels down to a single tumor molecule in a tube of blood, to identify recurrence earlier and to help optimize treatment decisions.

natera.com/oncology

Oncology Frontier 肿瘤瞭望

Oncology Frontier is a leading Chinese medical media platform dedicated to delivering timely, cutting-edge oncology updates worldwide. Covering around 100 international and domestic academic conferences annually, we conduct over 3,000 interviews with key opinion leaders. Our mission is to keep Chinese healthcare professionals informed of global advances in oncology by fostering academic exchange on latest research, innovative technology, and clinical practice between Chinese and international experts. At WCLC 2025, we will host MEET WCLC Daily Highlights Program to enhance awareness of Chinese research and engagement of Chinese oncologists in IASLC and the WCLC community.

ioncol.com

Personalis

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.

personalis.com

The National Comprehensive Cancer Network (NCCN)

The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.

nccn.org

The Ricky Rubio Foundation

The Ricky Rubio Foundation is a non-profit organization dedicated to fighting lung cancer through awareness, research, and patient support. With 41/2002, we turn the law into a message: a clothing collection that raises awareness of every patient’s right to molecular diagnosis. We also proudly join the Wellness Challenge to promote physical activity as a powerful ally in recovery and long-term wellbeing. Because personalized treatment starts with awareness—and movement.

therickyrubiofoundation.org

The White Ribbon Project

The White Ribbon Project is a grassroots movement changing public perception of lung cancer by promoting the truth that anyone with lungs can get lung cancer. Founded by survivor Heidi Nafman-Onda and her husband Dr. Pierre Onda, it builds community, raises awareness, and advocates for issues important to the lung cancer community such as lung cancer screening, biomarker testing, and research funding. Thousands of handmade white ribbons have been shared worldwide to bring hope, connection, and urgency to this silent epidemic

thewhiteribbonproject.org

PExA AB

PExA delivers a unique non-invasive sampling platform from the small airways, enabling biomarker discovery where lung diseases begin. Actively used by leading research groups in Lung Cancer studies, PExA also offers strategic opportunities for pharma and diagnostic companies. Potential applications include early detection, screening, and supporting drug and diagnostic development.

pexa.se/

Japan Lung Cancer Society (JLCS)

Founded in 1960, the Japan Lung Cancer Society (JLCS) is the largest professional organization in Japan devoted to lung cancer research, prevention, diagnosis, treatment, and advocacy. With more than 7,500 members, including physicians, researchers, and allied health professionals, the JLCS promotes multidisciplinary collaboration and advances science through annual meetings, educational programs, and publications. The society actively fosters international exchange—particularly with the IASLC and other global partners—to share knowledge and improve patient outcomes worldwide. The JLCS remains committed to reducing the burden of lung cancer and, ultimately, to realizing a world free from the disease.

haigan.gr.jp/en/